Skip to main content
. 2016 Dec 23;6(1):e1261779. doi: 10.1080/2162402X.2016.1261779

Figure 4.

Figure 4.

Tim-3 is upregulated in TIL after in vivo anti-PD-1 treatment, and is further upregulated upon in vitro PD-1 blockade in murine HNC model. C57BL/6 mouse were injected 1 × 106 MEER cells in the neck, anti-mouse PD-1 mAb was given as treatment; all the mouse were scarified around day 36 after injection of tumor cells. Freshly isolated tumor-infiltrating lymphocytes from murine HNC model were analyzed for Tim-3 expression by flow cytometry. (A) Representative flow plots of Tim-3 expression pattern in no treatment group and anti-PD-1 treated group were shown in CD8+ and CD4+CD25lo/− T cells. (B, C) Summary data of Tim-3 MFI and %Tim-3+ cells in tumor-infiltrating CD8+ and CD4+CD25lo/− T cells. (n = 6) Significance were calculated by unpaired t test, *p < 0.05, **p < 0.001. (D) Freshly isolated splenocytes were incubated with anti-PD-1 mAb or IgG4 for 48 h and Tim-3 expression was assessed by flow cytometry. Summary data of Tim-3 MFI in CD8+ and CD4+ T cells from splenocytes.(n = 6) Significance were calculated by two-way ANOVA, *p < 0.05, **p < 0.001.